CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia Classification of Deaths in Cardiovascular Outcomes Trials Known Unknowns and Unknown Unknowns Genotype-Guided Strategy for Oral P2Y12 Inhibitors Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents Management of two major complications in the cardiac catheterisation laboratory: the no-reflow phenomenon and coronary perforations Association Between Living in Food Deserts and Cardiovascular Risk High-Risk Coronary Atherosclerosis Is It the Plaque Burden, the Calcium, the Lipid, or Something Else? A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial

Consensus06 April 2020

JOURNAL: JACC Cardiovasc Interv and Catheter Cardiovasc In Article Link

Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the Coronavirus Disease 2019 (COVID-19) Pandemic: An ACC /SCAI Consensus Statement

PB Shah, FGP Welt, E Mahmud et al. Keywords: COVID-19; TAVR; valvular and structural heart disease; HF; triage intervention

Full Text PDF

The COVID-19 pandemic has strained health care resources around the world causing many institutions to curtail or stop elective procedures. This has resulted in the inability to care for patients valvular and structural heart disease (SHD) in a timely fashion potentially placing these patients at increased risk for adverse cardiovascular complications including congestive heart failure and death. The effective triage of these patients has become challenging in the current environment as clinicians have had to weigh the risk of bringing susceptible patients into the hospital environment during the COVID-19 pandemic versus the risk of delaying a needed procedure. In this document, we suggest guidelines as to how to triage patients in need of SHD interventions and provide a framework of how to decide when it may be appropriate to proceed with intervention despite the ongoing pandemic. In particular, we address the triage of patients in need of trans-catheter aortic valve replacement and percutaneous mitral valve repair. We also address procedural issues and considerations for the function of structural heart disease teams during the COVID-19 pandemic.